1. Introduction {#sec1-cells-08-01286}
===============

ATP-binding cassette (ABC) transporters are energy-dependent efflux pumps responsible for the active efflux of drugs, thereby reducing their intracellular concentration. Due to overexpression of ABC transporters in tumor cells, multidrug resistance (MDR) develops, which leads to the failure of chemotherapy with fatal consequences for cancer patients \[[@B1-cells-08-01286]\]. P-glycoprotein, being a well-known member among the ABC transporter family, is encoded by the *ABCB1*/*MDR1* gene. It is an important determinant of MDR \[[@B2-cells-08-01286],[@B3-cells-08-01286],[@B4-cells-08-01286]\] and upregulated in many clinically resistant and refractory tumors \[[@B5-cells-08-01286],[@B6-cells-08-01286]\]. Its overexpression in tumor cells is associated with efficient extrusion of a large number of established anticancer drugs and natural cytotoxic products out of cancer cells, representing a major drawback of cancer chemotherapy \[[@B7-cells-08-01286]\]. Resistance is either inherently present or will be acquired during chemotherapy \[[@B8-cells-08-01286],[@B9-cells-08-01286],[@B10-cells-08-01286]\]. Hence, P-glycoprotein (P-gp) represents an important target to search for pharmacological inhibitors to overcome MDR \[[@B11-cells-08-01286]\]. Targeting P-gp to overcome MDR is of importance to achieve higher success rates for chemotherapy. The concept is to combine P-gp inhibitors with established chemotherapy drugs to resensitize tumors \[[@B12-cells-08-01286],[@B13-cells-08-01286],[@B14-cells-08-01286],[@B15-cells-08-01286]\].

Machine learning and artificial intelligence are recently acquiring increasing interest in the area of drug discovery \[[@B16-cells-08-01286],[@B17-cells-08-01286],[@B18-cells-08-01286]\] because these methods have an enormous potential to speed up the preclinical development processes at minimal costs. For this purpose, we utilized a machine learning strategy in order to establish a prediction platform that allows to predict whether a given compound behaves as a substrate or an inhibitor of P-gp.

Available natural compound databases serve as an invaluable source to identify novel lead compounds that possess activity against certain diseases or disorders by focusing on particular target biomarker proteins. As a majority of established anticancer drugs are of natural origin \[[@B19-cells-08-01286]\], natural products may serve as lead compounds for derivatization to obtain novel chemical entities with improved pharmacological features. Analyses of the interaction between the compounds and the target protein with molecular docking provide clues about the possible binding mode and binding energy, as we reported before \[[@B11-cells-08-01286],[@B20-cells-08-01286],[@B21-cells-08-01286]\]. Selecting P-gp as target protein, the interaction of test compounds can be compared with that of known P-gp inhibitors, such as verapamil, valspodar, tariquidar, or elacridar, in order to assess their binding properties, docking poses, and binding energies. In those cases, where the test compounds yielded by using the P-gp modulator prediction platform possess similar docking poses and comparable binding energies as known inhibitors, it could be concluded that these compounds may be potential P-gp inhibitors.

In the present study, we used machine learning strategies to establish such a P-gp modulator prediction platform for compounds by using defined chemical descriptors to predict whether a given compound can behave as a substrate or an inhibitor of P-gp. Selected compounds from inhibitor or substrate classes were subjected to molecular docking for further verification and compared with known P-gp inhibitors and substrates.

2. Material and Methods {#sec2-cells-08-01286}
=======================

2.1. Preparation of Compound List and Calculation of Chemical Descriptors {#sec2dot1-cells-08-01286}
-------------------------------------------------------------------------

For the P-gp modulator/non-modulator prediction model, a compound list with modulators and non-modulators from Broccatelli et al. \[[@B22-cells-08-01286]\] was used. Compounds for learning and validation steps were randomly selected. Thirty-two modulator and thirty-two non-modulator compounds were used for the learning step, while 16 modulator and 16 non-modulator substances were used for the validation step ([Table 1](#cells-08-01286-t001){ref-type="table"}). For the P-gp inhibitor/substrate prediction model, a list of P-gp substrates and inhibitors was prepared by referring to the literature \[[@B23-cells-08-01286]\], yielding a total of 60 compounds (34 inhibitors, 26 substrates). Again, compounds for learning and validation steps were randomly selected. Forty compounds (20 inhibitors, 20 substrates) were used for learning and model establishment. The remaining 20 compounds (14 inhibitors, 6 substrates) were used for the external validation step ([Table 2](#cells-08-01286-t002){ref-type="table"}).

Data Warrior software is a multipurpose chemistry data visualization and data analysis program that calculates various molecular descriptors and properties for a given set of compounds. It was used to calculate the chemical descriptors as previously reported \[[@B24-cells-08-01286],[@B25-cells-08-01286]\]. After calculation of the 32 chemical descriptors, correlation coefficients between descriptors and correlation of the descriptors with the P-gp modulator category (substrate or inhibitor) were determined using SPSS statistics software version 23.0.0.3 (IBM, Armonk, NY: IBM Corp, USA). If the correlation coefficient between the P-gp modulator category (substrate or inhibitor) and a certain descriptor was below 0.1, this descriptor was omitted. Only descriptors correlating with the P-gp modulator (substrate or inhibitor) category above 0.1 were selected for further processing. As a next step, descriptors having a pairwise correlation coefficient to the P-gp modulator category lower than 0.9 were excluded \[[@B26-cells-08-01286]\]. By this strategy, relevant descriptors without an issue of over-fitting can be selected.

2.2. P-Glycoprotein Modulator Prediction Model Establishment {#sec2dot2-cells-08-01286}
------------------------------------------------------------

At first, a model, which can predict whether a given compound is a P-gp modulator, was built by using the compound list from Broccatelli et al. \[[@B22-cells-08-01286]\] After applying the descriptor selection criteria by considering the relevancy and over-fitting issues, "logP", "H-donors", "polar surface area", "ligand efficiency dependent lipophilicity", "molecular complexity", "stereo centers", "rotatable bonds", "rings closures", "aromatic rings", "sp-3 atoms", "amides", "amines", "alkyl-amines, "and "basic nitrogens" were considered for the preparation of the P-gp modulator/non-modulator prediction model. Various classification algorithms with the leave-one-out random sampling method were tested, i.e., k-Nearest Neighboring (kNN), Neural Network, Random Forest (RF), and Support Vector Machine (SVM). Receiver operating characteristic (ROC) curves are depicted in [Figure 1](#cells-08-01286-f001){ref-type="fig"}. The receiver operating characteristic (ROC) curve plotted the true positive rate (= sensitivity) against the false positive rate (= 1-specificity). The RF algorithm performed better than the other classification algorithms both in learning and validation steps. The overall performance for the established model based on RF algorithm is summarized in [Table 3](#cells-08-01286-t003){ref-type="table"}. The establishment of the P-gp modulator/non-modulator and P-gp inhibitor/substrate prediction models were performed by using the machine learning software Orange (Ljubljana, Slovenia) \[[@B27-cells-08-01286]\].

After applying the descriptor selection criteria by considering the relevancy and over-fitting issues, "logP", "total surface area", "shape index", "molecular flexibility", "rotatable bonds", "aromatic rings", "aromatic atoms", "aromatic nitrogens", "basic nitrogens", "symmetric atoms", and "acidic oxygens" were considered for P-gp inhibitor/substrate prediction model preparation. Various classification algorithms with the leave-one-out random sampling method were tested, i.e., kNN, Neural Network, RF, and SVM. The ROC curves are depicted in [Figure 2](#cells-08-01286-f002){ref-type="fig"}. The RF algorithm performed better than the other classification algorithms. The overall performance for the established model is summarized in [Table 4](#cells-08-01286-t004){ref-type="table"}.

In order to evaluate the model performance further and select potential inhibitors, a P-gp modulator compound list consisting of 643 compounds from ChEMBL was used.

2.3. Molecular Docking {#sec2dot3-cells-08-01286}
----------------------

The recently published human P-gp structure was used (nanodisc reconstituted in complex with UIC2 fab and paclitaxel at the drug-binding pocket, PDB ID: 6QEX, in the absence of a lipid bilayer) \[[@B28-cells-08-01286]\]. The Fab chains were deleted. The bound ligands marked as "HETATM" including taxol were also deleted from the PDB structure file in order to prevent interference with molecular docking. The preparation of the final receptor structure as ".pdbqt" file was performed with Autodock tools 1.5.7. Selected compounds from inhibitor and substrate classes have been subjected to an automated and comprising molecular docking campaign by using the high-performance supercomputer MOGON (Johannes Gutenberg University, Mainz). Compound flexibilities were taken into account and a rigid receptor structure was used. At first, three independent screening of all 643 compounds from ChEMBL with Autodock Vina algorithm was performed by focusing on the drug-binding pocket of P-gp, where the majority of the known inhibitors and substrates bind to. The grid parameters are listed in [Table 5](#cells-08-01286-t005){ref-type="table"}.

Afterward, the top 20 compounds in terms of binding energy yielded from both inhibitor and substrate predictions were selected for molecular docking. Each molecular docking was based on three independent dockings each consisting of 2,500,000 calculations. This means that each data point represents the mean value of 7,500,000 individual MOGON-based calculations. The Autodock 4 algorithm was used for defined molecular docking calculations on the drug-binding pocket of P-gp as described before \[[@B11-cells-08-01286]\], and Visual Molecular Dynamics (VMD) software (Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign) was used for the visualization of the docking poses. Estimated inhibition constants were calculated by the Autodock algorithm with the equation:$$Ki = \exp\left( \frac{\mathsf{\Delta}G}{R*T} \right)$$ *Ki* (M)Δ*G* (cal/mol) = 1000 \* LBE (lowest binding energy, kcal/mol)*R* (cal/mol-K): gas constant, 1.986 cal/mol-K*T* (K): room temperature, 298 K

2.4. Boxplot Analysis {#sec2dot4-cells-08-01286}
---------------------

The distribution of the values for the descriptors used for the P-gp inhibitor/substrate prediction model and the comparison for the predicted inhibitors and substrates among the ChEMBL P-gp modulator list were subjected to Boxplot analysis using Microsoft Excel 2019 (Microsoft, USA). Statistical significances were evaluated by the t-test (two-tailed, two-sample unequal variance).

3. Results {#sec3-cells-08-01286}
==========

3.1. P-glycoprotein Modulator Predictions {#sec3dot1-cells-08-01286}
-----------------------------------------

The P-gp modulator/non-modulator prediction model was evaluated with the validation set as mentioned in the corresponding method part. The RF algorithm reached 0.938 for all parameters. The ChEMBL P-gp modulator list of 643 compounds was tested, and 641 out of 643 substances were correctly predicted as modulators.

The P-gp inhibitor/substrate prediction model with the ChEMBL P-gp modulator list of 643 compounds was evaluated. A total of 493 substances were predicted as inhibitors, and 150 compounds were predicted as substrates. Subjecting all compounds to Autodock Vina screening allowed to rank them according to their binding energies. The top 20 inhibitor predictions with strong interaction to P-gp are shown in [Table 6](#cells-08-01286-t006){ref-type="table"}. These inhibitors were selected for subsequent molecular docking. The top 20 substrate predictions with strong interaction to P-gp are shown in [Table 7](#cells-08-01286-t007){ref-type="table"}. These substrates were also selected substances for subsequent molecular docking. The complete predictions for all 493 inhibitors together with their binding affinities to P-gp are shown in [Supplementary Table S1](#app1-cells-08-01286){ref-type="app"}, while all predictions for the 150 substrates and their affinities to P-gp are listed in [Supplementary Table S2](#app1-cells-08-01286){ref-type="app"}. The average lowest binding energy (LBE) was -8.155 for the inhibitors and -9.289 for the substrates.

Among the 493 inhibitor compounds were 117 natural products (= 23.7%), while all other compounds were of synthetic origin ([Supplementary Table S1](#app1-cells-08-01286){ref-type="app"}). The proportion of natural products was higher among the predicted P-gp substrates (69/150 = 46%) ([Supplementary Table S2](#app1-cells-08-01286){ref-type="app"}). This trend was even more apparent if we focused on the top 20 inhibitor or substrate compounds only ([Table 6](#cells-08-01286-t006){ref-type="table"} and [Table 7](#cells-08-01286-t007){ref-type="table"}). Here, 2/20 (= 10%) were predicted inhibitors, but 11/20 (= 55%) were predicted substrates, indicating that P-glycoprotein may expel natural xenobiotics from cells with higher probability.

3.2. Molecular Docking {#sec3dot2-cells-08-01286}
----------------------

After running the prediction model on the P-gp modulator list from ChEMBL and the Autodock VINA screening, the top 20 compounds from the inhibitor class and the top 20 compounds from the substrate class were selected for molecular docking analyses on human P-gp. The lowest binding energies (LBE) and predicted inhibition constants are listed in [Table 8](#cells-08-01286-t008){ref-type="table"} for the inhibitors and [Table 9](#cells-08-01286-t009){ref-type="table"} for the substrates.

The negative control compounds (oxprenolol, promazine, riluzole) revealed weaker interaction with P-gp ([Table 10](#cells-08-01286-t010){ref-type="table"}) and slightly different docking pose as well ([Figure 3](#cells-08-01286-f003){ref-type="fig"}).

As can be seen in [Figure 4](#cells-08-01286-f004){ref-type="fig"}, the predicted inhibitors possessed similar docking poses as elacridar at the drug-binding pocket of P-gp. Similar results were observed for the substrates: The predicted substrates revealed similar docking poses as doxorubicin. Hence, these results validated the precision and reliability of the model.

Predicted inhibitors and substrates interact with P-gp significantly stronger than the negative control compounds. This is clear both from the binding energies and predicted inhibition constants. Binding energies of non-modulators are within −5.380 (piluzole) to −6.933 (promazine) kcal/mol and the predicted inhibition constants are within 8.273--114.080 µM, whereas binding energies for the predicted substrates are within −7.337 (vindoline) to −12.500 (latilagescene G) and for the predicted inhibitors −8.900 (3-methylcholanthrene) to −13.537 (karavoate P). Predicted inhibition constants for the predicted substrates are within 0.001--4.363 and for the predicted inhibitors 0.0002--0.300 µM. Docking pose of the negative control compounds differs from that of inhibitors and substrates. Overall, it can be speculated that the predicted inhibitors interact with P-gp stronger than the predicted substrates and the non-modulators are making weak interactions with P-gp and they bind to a different site.

The distribution of the values for the descriptors used to build the model and the comparison for the predicted inhibitors and substrates in terms of those descriptor values were performed with Boxplot analysis. As can be seen from [Figure 5](#cells-08-01286-f005){ref-type="fig"}, the inhibitors revealed significantly different values for all descriptors except logP and acidic oxygens. The average values of descriptors for inhibitors and substrates are listed in [Table 11](#cells-08-01286-t011){ref-type="table"}.

4. Discussion {#sec4-cells-08-01286}
=============

In the present study, we utilized machine learning methods based on leave-one-out random sampling in order to develop a P-gp modulator prediction platform by using chemical descriptors. The main focus was to predict whether a given compound can behave as substrate or inhibitor of P-gp. The RF classification algorithm (AUC:0.774) outperformed the other tested algorithms (kNN---0.676, Neural Network---0.745, SVM---0.720). Performance scores for the external validation set were even higher than the learning set with better sensitivity (0.786 vs. 0.750), specificity (0.833 vs. 0.700), overall prediction accuracy (0.800 vs. 0.725), and precision (0.917 vs. 0.714). Further testing with the P-gp modulator list from ChEMBL yielded promising results with accurate predictions. Four compounds from inhibitor and four compounds from substrate prediction list were selected for molecular docking analyses. Validations with molecular docking on a recently released human P-gp structure were performed in terms of binding energy and docking poses by including known inhibitor (elacridar) and substrate (doxorubicin) as controls. Curcumin, miconazole, tacrolimus, and venlafaxine revealed a similar docking pose at the drug-binding pocket of P-gp with comparable binding energies with that of elacridar. MK-3207, rifampin, vindoline, and voacamine revealed similar docking poses and comparable binding energy with those of doxorubicin. Overall, the precision and reliability of the model were further confirmed.

Machine learning and artificial intelligence attracted increasing interest in the drug discovery area \[[@B18-cells-08-01286],[@B29-cells-08-01286],[@B30-cells-08-01286]\], and utilizing these methods possess great potential for drug discovery, as they save time and costs during the preclinical steps. The RF algorithm depends on multiple decision trees that are built based on the training data, and a majority voting scheme is used to make classification or regression predictions \[[@B31-cells-08-01286]\]. RF application to drug discovery has been recently reported, and it outperformed other algorithms such as SVM and NN in terms of feature selection \[[@B32-cells-08-01286]\].

There are various studies in the literature that utilized machine-learning strategies focusing on P-gp. One study pointed out a P-gp substrate prediction model based on RF algorithm to estimate transport potential for central nervous system drugs, accuracy lies between 0.713 and 0.846 whereas precision is between 0.633 and 0.777 \[[@B33-cells-08-01286]\]. Our P-gp modulator prediction model involves an accuracy of 0.953 for the learning set and 0.938 for the validation set, and our P-gp inhibitor prediction model has an accuracy value of 0.725 for the learning set and 0.800 for the validation set. In terms of precision, our models also perform better. Modulator prediction model involves a precision of 0.968 for the learning set and 0.938 for the validation set. Inhibitor prediction model has a 0.714 precision for the learning set and 0.917 for the validation set. Similarly, a P-gp substrate efflux ratio prediction model has been recently reported based on SVM algorithm \[[@B34-cells-08-01286]\]. The affinities of flavonoids to P-gp have been evaluated with an SVM-based model and a high correlation with the experimental data has been achieved \[[@B35-cells-08-01286]\]. Another study involving P-gp inhibitor prediction was performed for chalcone derivatives and selected inhibitor candidates were analyzed in terms of their docking pose on a homology model of human P-gp \[[@B36-cells-08-01286]\]. The prediction of blood--brain barrier permeability mechanism of central nervous system drugs has been utilized with an SVM-based model \[[@B37-cells-08-01286]\]. Binding pattern prediction based on pharmacophore ensemble/SVM method for potential P-gp inhibitors was also recently reported \[[@B38-cells-08-01286]\]. Another SVM-based model coupled with molecular docking aimed to predict whether a given compound may act as P-gp substrate, the accuracy lies between 0.750 and 0.800, specificity between 0.750 and 0.810, and sensitivity between 0.740 and 0.790 \[[@B39-cells-08-01286]\]. Our modulator prediction model outperforms that model in all those parameters. Our inhibitor prediction model outperforms in the validation set. Similarly, in 2004, SVM-based P-gp substrate prediction model was reported; sensitivity was 0.812, specificity was 0.792, and accuracy was 0.794 \[[@B40-cells-08-01286]\]. Our modulator prediction model outperforms that model in all those parameters. Our inhibitor prediction model outperforms in the validation set for the specificity and accuracy parameters. In general, these previously published studies have certain disadvantages, e.g., low performance scores in terms of prediction, focusing on only P-gp substrate prediction or molecular docking with homology models but not crystal structures. Our model is superior compared to the previously published studies for several reasons. It is based on leave-one-out random sampling RF algorithm, focused on both natural as well as synthetic compounds, has high sensitivity, specificity, predictive accuracy, and precision to predict at first P-gp modulator/non-modulator and as a next step to predict P-gp substrate/inhibitor depending on various chemical descriptors, and it was coupled with molecular docking using the recently released crystal structure of human P-gp. The fact that predictions on the P-gp modulator list of compounds from ChEMBL was validated with accurate molecular docking results was also advantageous for our model. Furthermore, after the initial compound screening, selected inhibitors revealed similar docking poses as elacridar (as positive control for an inhibitor) and selected substrates revealed similar docking poses as doxorubicin (as positive control for a substrate). Non-modulators have significantly weaker interaction with P-gp and they bind to a slightly different position. Overall, those observations provide further clues for the reliability of the prediction model.

Selected inhibitors and substrates after the virtual screening are supported by literature; astemizole \[[@B41-cells-08-01286]\], cryptotanshinone \[[@B42-cells-08-01286]\], dihydrocytochalasin B \[[@B43-cells-08-01286]\], jolkinol B \[[@B44-cells-08-01286]\], latilagascenes D \[[@B45-cells-08-01286]\], lonafarnib \[[@B46-cells-08-01286]\], tariquidar \[[@B12-cells-08-01286]\], zosuquidar \[[@B47-cells-08-01286]\], acetyldigitoxin \[[@B48-cells-08-01286]\], bromocriptine \[[@B49-cells-08-01286]\], candesartan cilexetil \[[@B50-cells-08-01286]\], cepharanthin \[[@B51-cells-08-01286]\], cytochalasin E \[[@B52-cells-08-01286]\], digitoxin \[[@B53-cells-08-01286]\], digoxin \[[@B54-cells-08-01286]\], dihydroergosrictine \[[@B55-cells-08-01286]\], dofequidar \[[@B56-cells-08-01286]\], ergocristine \[[@B55-cells-08-01286]\], irinotecan \[[@B57-cells-08-01286]\], latilagascenes E \[[@B45-cells-08-01286]\], MK-3207 \[[@B58-cells-08-01286]\], paclitaxel \[[@B59-cells-08-01286]\], vindoline \[[@B60-cells-08-01286]\].

Many cancer types involve P-gp overexpression, which is associated with increased efflux of established anticancer drugs and natural cytotoxic products out of cancer cells. This phenomenon represents a major drawback of cancer chemotherapy with limitations in killing tumor populations due to MDR \[[@B61-cells-08-01286],[@B62-cells-08-01286]\]. P-gp overexpression is indeed one of the main reasons for MDR and thus inadequate chemotherapy success rate. Targeting P-gp is critical to achieve high success rates for chemotherapy, therefore, identification of novel P-gp inhibitors is critical in that regard.

Our prediction platform for P-gp modulators facilitates to predict whether a given compound can behave as a substrate or an inhibitor of P-gp. The selection of potential inhibitors can be further validated by molecular docking and the comparison of the binding energy and docking pose with those of known P-gp inhibitors. As a next step in the future, our model may be helpful to identify potential novel P-gp inhibitors and to develop effective chemotherapy strategies involving combination therapy with targeted chemotherapy drugs and identified P-gp inhibitors.

5. Conclusion {#sec5-cells-08-01286}
=============

In the present study, we established P-gp modulator/non-modulator and inhibitor/substrate prediction models based on the RF algorithm and leave-one-out random sampling. Validation with molecular docking was performed. The identification of novel P-gp inhibitors is critical to overcome MDR and to achieve better chemotherapy strategies. This model can predict whether a given compound can behave as substrate or inhibitor of P-gp, and will be, thus, helpful to identify potential P-gp inhibitors.

Parts of this research were conducted using the supercomputer Mogon and/or advisory services offered by Johannes Gutenberg University Mainz (hpc.uni-mainz.de), which is a member of the AHRP (Alliance for High-Performance Computing in Rhineland Palatinate, [www.ahrp.info](www.ahrp.info)) and the Gauss Alliance e.V. The authors gratefully acknowledge the computing time granted on the supercomputer Mogon at Johannes Gutenberg University Mainz (hpc.uni-mainz.de).

The following are available online at <https://www.mdpi.com/2073-4409/8/10/1286/s1>, Table S1: Prediction of P-gp inhibitors identified by the random forest classification algorithm using the ChEMBL P-gp modulator list of 493 compounds, Table S2: Prediction of P-glycoprotein substrates identified by the RF classification algorithm using the ChEMBL P-gp modulator list of 150 compounds.
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![Receiver operating characteristic (ROC) curves of k Nearest Neighboring (kNN), Neural Network, Random Forest (RF), and Support Vector Machine (SVM) classification algorithms based on random leave-one-out sampling for the P-gp modulator/non-modulator prediction model for the learning step.](cells-08-01286-g001){#cells-08-01286-f001}

![ROC curves of kNN, Neural Network, RF, and SVM classification algorithms based on random leave-one-out sampling for the P-gp inhibitor/substrate prediction model for the learning step.](cells-08-01286-g002){#cells-08-01286-f002}

![Molecular docking results for selected non-modulators (pink).](cells-08-01286-g003){#cells-08-01286-f003}

![Molecular docking results for selected inhibitors (red) and substrates (green) yielded from the P-gp inhibitor/substrate prediction model. Elacridar (blue) and doxorubicin (yellow) were selected as control drugs.](cells-08-01286-g004){#cells-08-01286-f004}

![Boxplot analysis of the descriptors used for the model and comparison of the predicted inhibitors and substrates.](cells-08-01286-g005){#cells-08-01286-f005}

cells-08-01286-t001_Table 1

###### 

Compounds selected for learning and external validation for the P-glycoprotein (P-gp) modulator/non-modulator prediction model.

  Learning Set                  External Validation Set                                                        
  ----------------------------- ------------------------- ----------------- --------------- ------------------ ---------------
  Escitalopram                  Modulator                 Hydroxyzine       Non-modulator   Terfenadine        Modulator
  Simvastatin acid              Modulator                 Oxybutynin        Non-modulator   Prazosin           Modulator
  Neostigmine                   Modulator                 Ethosuximide      Non-modulator   Prednisone         Modulator
  Zolmitriptan                  Modulator                 Warfarin          Non-modulator   Chloroquine        Modulator
  Atomoxetine                   Modulator                 Mexilitene        Non-modulator   Lopinavir          Modulator
  Methysergide                  Modulator                 Sulpiride         Non-modulator   Prednisolone       Modulator
  Famciclovir                   Modulator                 Thiopental        Non-modulator   Vincristine        Modulator
  Lovastatin acid               Modulator                 Lamotrigine       Non-modulator   Sertraline         Modulator
  Darifenacin                   Modulator                 Diphenhydramine   Non-modulator   Loperamide         Modulator
  Paliperidone                  Modulator                 Enoxacin          Non-modulator   Etoposide          Modulator
  Trospium                      Modulator                 Methylphenidate   Non-modulator   Indinavir          Modulator
  Aprepitant                    Modulator                 Itraconazole      Non-modulator   Dipyridamole       Modulator
  Apomorphine                   Modulator                 Nortriptyline     Non-modulator   Mitoxantrone       Modulator
  Cetirizine                    Modulator                 Galantamine       Non-modulator   Cimetidine         Modulator
  Cyclosporin A                 Modulator                 Ramelteon         Non-modulator   Bromocriptine      Modulator
  Labetalol                     Modulator                 Rivastigmine      Non-modulator   Reserpine          Modulator
  Amisulpride                   Modulator                 Ropivacaine       Non-modulator   Oxprenolol         Non-modulator
  5-Hydroxymethyl tolterodine   Modulator                 Zonisamide        Non-modulator   Alprazolam         Non-modulator
  Cabergoline                   Modulator                 Zolpidem          Non-modulator   Oxcarbazepine      Non-modulator
  Ximelagatran                  Modulator                 Sulfasalazine     Non-modulator   Tolterodine        Non-modulator
  Hoechst 33342                 Modulator                 Metoclopramide    Non-modulator   Zaleplon           Non-modulator
  Rhodamine 123                 Modulator                 Nalmefene         Non-modulator   Cyclobenzaprine    Non-modulator
  Actinomycin D                 Modulator                 Oxycodone         Non-modulator   Nimodipine         Non-modulator
  Olanzapine                    Modulator                 Topiramate        Non-modulator   Riluzole           Non-modulator
  Ranitidine                    Modulator                 Hydrocodone       Non-modulator   Tiagabine          Non-modulator
  Astemizole                    Modulator                 Rosuvastatin      Non-modulator   Nalbuphine         Non-modulator
  Verapamil                     Modulator                 Tropisetron       Non-modulator   Duloxetine         Non-modulator
  Ziprasidone                   Modulator                 Varenicline       Non-modulator   Pravastatin acid   Non-modulator
  Chlorpromazine                Modulator                 Clemastine        Non-modulator   Promazine          Non-modulator
  Clozapine                     Modulator                 Clonazepam        Non-modulator   Bromazepam         Non-modulator
  Trimethoprim                  Modulator                 Ropinirole        Non-modulator   Lorazepam          Non-modulator
  Paroxetine                    Modulator                 Solifenacin       Non-modulator   Mirtazapine        Non-modulator

cells-08-01286-t002_Table 2

###### 

Compounds selected for learning and external validation for the P-gp inhibitor/substrate prediction model.

  Learning Set     External Validation Set                                                                           
  ---------------- ------------------------- ---------------- ----------- -------------- ----------- --------------- -----------
  Ginsenoside      Inhibitor                 Epirubicin       Substrate   Agosterol      Inhibitor   Colchicin       Substrate
  Laniquidar       Inhibitor                 Etoposide        Substrate   Amiodarone     Inhibitor   Dexamethazone   Substrate
  Loratidine       Inhibitor                 Fexofenadine     Substrate   Amorinin       Inhibitor   Digoxin         Substrate
  Mibefradil       Inhibitor                 Hoechst 33342    Substrate   Apigenin       Inhibitor   Docetaxel       Substrate
  Naringenin       Inhibitor                 Idarubicin       Substrate   Atorvastatin   Inhibitor   Doxorubicin     Substrate
  Pgp-4008         Inhibitor                 Irinotecan       Substrate   Atovaquone     Inhibitor   Daunorubicin    Substrate
  Phloretin        Inhibitor                 Kaempferol       Substrate   Biochanin      Inhibitor                   
  Quercetin        Inhibitor                 Loperamide       Substrate   Biricodar      Inhibitor                   
  Quinine          Inhibitor                 Mitomycin        Substrate   Catechin       Inhibitor                   
  Rotenone         Inhibitor                 Mitoxantrone     Substrate   Cefoperazone   Inhibitor                   
  Sakuranetin      Inhibitor                 Ondansetron      Substrate   Chrysine       Inhibitor                   
  Sertraline       Inhibitor                 Paclitaxel       Substrate   Cyclosporine   Inhibitor                   
  Sinensetin       Inhibitor                 Procyanidin B2   Substrate   Diltiazem      Inhibitor                   
  Stigmasterol     Inhibitor                 Rhodamine 123    Substrate   Elacridar      Inhibitor                   
  Syringaresinol   Inhibitor                 Tenoposide       Substrate                                              
  Tamoxifen        Inhibitor                 Topotecan        Substrate                                              
  Tariquidar       Inhibitor                 Vinblastine      Substrate                                              
  Valspodar        Inhibitor                 Vincristine      Substrate                                              
  Verapamil        Inhibitor                 Vindesine        Substrate                                              
  Zosuquidar       Inhibitor                 Vinorelbine      Substrate                                              
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###### 

Performance of the P-gp modulator/non-modulator prediction model based on the RF classifier algorithm.

  Steps                     Sensitivity   Specificity   Overall Predictive Accuracy   Precision
  ------------------------- ------------- ------------- ----------------------------- -----------
  **Learning**              0.938         0.969         0.953                         0.968
  **External Validation**   0.938         0.938         0.938                         0.938
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###### 

Performance of the P-gp inhibitor/substrate prediction model based on the RF classifier algorithm.

  Steps                     Sensitivity   Specificity   Overall Predictive Accuracy   Precision
  ------------------------- ------------- ------------- ----------------------------- -----------
  **Learning**              0.750         0.700         0.725                         0.714
  **External Validation**   0.786         0.833         0.800                         0.917
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###### 

Grid parameters for molecular docking analyses on human P-gp.

                         x         y         z
  ---------------------- --------- --------- ---------
  **Number of Points**   126       98        116
  **Grid Center**        168.614   166.372   162.000
  **Grid Spacing (Å)**   0.375               
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###### 

Prediction of the top 20 P-gp inhibitors identified by the RF classification algorithm using the ChEMBL P-gp modulator list of 493 compounds. The results were validated by determining the binding affinities using Autodock VINA.

  Name                     ChEMBL ID       Inhibitor Probability   Class       VINA LBE (kcal/mol)
  ------------------------ --------------- ----------------------- ----------- ---------------------
  Karavoate P              CHEMBL1641677   0.849                   Synthetic   −12.200 ± 1.212
  Tribenzoylbalsaminol F   CHEMBL1928854   0.549                   Synthetic   −12.033 ± 0.896
  Zosuquidar               CHEMBL444172    0.513                   Synthetic   −11.967 ± 0.058
  Latilagascenes D         CHEMBL435917    0.566                   Synthetic   −11.700 ± 0.001
  Dihydrocytochalasin B    CHEMBL2074735   0.513                   Synthetic   −11.367 ± 0.231
  Jolkinoate I             CHEMBL2315618   0.593                   Synthetic   −11.300 ± \<0.001
  Karavoate K              CHEMBL1641672   0.849                   Synthetic   −11.267 ± 0.493
  Fanchinin                CHEMBL176045    0.586                   Synthetic   −11.233 ± 0.208
  Latilagascene I          CHEMBL511018    0.586                   Synthetic   −11.167 ± 0.058
  Karavoate L              CHEMBL1641673   0.766                   Synthetic   −11.133 ± 0.808
  3-Methylcholanthrene     CHEMBL40583     0.788                   Synthetic   −11.100 ± \<0.001
  Lonafarnib               CHEMBL298734    0.567                   Synthetic   −11.000 ± \<0.001
  Karavoate N              CHEMBL1641675   0.666                   Synthetic   −10.933 ± 0.058
  Tariquidar               CHEMBL348475    0.619                   Synthetic   −10.933 ± 0.404
  Pimozide                 CHEMBL1423      0.517                   Synthetic   −10.900 ± 0.100
  Karavoate I              CHEMBL1641670   0.766                   Synthetic   −10.767 ± 0.058
  Cryptotanshinone         CHEMBL187460    0.663                   Natural     −10.700 ± \<0.001
  Jolkinol B               CHEMBL489265    0.577                   Synthetic   −10.700 ± \<0.001
  Astemizole               CHEMBL296419    0.617                   Synthetic   −10.667 ± 0.115
  Metergoline              CHEMBL19215     0.732                   Natural     −10.600 ± \<0.001
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###### 

Prediction of P-gp substrates identified by the RF classification algorithm using the ChEMBL P-gp modulator list of 150 compounds. The results were validated by determining the binding affinities using Autodock VINA.

  Name                    ChEMBL ID       Substrate probability   Class       VINA LBE (kcal/mol)
  ----------------------- --------------- ----------------------- ----------- ---------------------
  Vindoline               CHEMBL526546    0.771                   Synthetic   −15.000 ± \<0.001
  Cepharanthin            CHEMBL2074948   0.614                   Natural     −12.600 ± \<0.001
  Latilagascene G         CHEMBL448193    0.514                   Synthetic   −12.300 ± \<0.001
  Mk3207                  CHEMBL1910936   0.733                   Synthetic   −12.167 ± 0.058
  Ergocristine            CHEMBL446315    0.767                   Natural     −12.067 ± 0.058
  Cytochalasin E          CHEMBL494856    0.6                     Natural     −11.800 ± \<0.001
  Jolkinoate L            CHEMBL2315621   0.567                   Synthetic   −11.533 ± 0.058
  Irinotecan              CHEMBL481       0.967                   Natural     −11.400 ± 0.819
  Latilagascenes E        CHEMBL373511    0.614                   Synthetic   −11.367 ± 0.116
  Dofequidar              CHEMBL65067     0.583                   Synthetic   −11.300 ± 0.001
  Acetyldigoxin           CHEMBL2074725   0.708                   Natural     −11.233 ± 0.808
  Dihydroergocristine     CHEMBL601773    0.767                   Natural     −11.133 ± 0.666
  Telcagepant             CHEMBL236593    0.517                   Synthetic   −11.067 ± 0.058
  Ergotamine              CHEMBL442       0.8                     Natural     −10.933 ± 0.058
  Candesartan Cilexetil   CHEMBL1014      0.567                   Synthetic   −10.900 ± 0.200
  Digoxin                 CHEMBL1751      0.708                   Natural     −10.833 ± 1.097
  Bromocriptine           CHEMBL493       0.767                   Natural     −10.800 ± 0.100
  Itrazole                CHEMBL64391     0.564                   Synthetic   −10.700 ± 0.436
  Digitoxin               CHEMBL254219    0.725                   Natural     −10.667 ± 0.462
  Paclitaxel              CHEMBL428647    0.808                   Natural     −10.633 ± 0.462
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###### 

Lowest binding energies (LBE) and predicted inhibition constants obtained by molecular docking of the top 20 P-gp inhibitors.

  P-gp Inhibitor                 AutoDock LBE (kcal/mol)   Predicted Inhibition Constant (µM)
  ------------------------------ ------------------------- ------------------------------------
  3-Methylcholanthrene           −8.900 ± 0.001            0.300 ± \<0.001
  Astemizole                     −9.693 ± 0.047            0.079 ± 0.007
  Cryptotanshinone               −9.010 ± 0.001            0.251 ± \<0.001
  Dihydrocytochalasin B          −10.460 ± 0.020           0.0212 ± 0.001
  Fanchinin                      −9.937 ± 0.067            0.0522 ± 0.006
  Jolkinoate I                   −10.440 ± 0.200           0.0232 ± 0.008
  Jolkinol B                     −10.250 ± 0.044           0.0307 ± 0.002
  Karavoate I                    −12.310 ± 0.235           0.001 ± \<0.001
  Karavoate K                    −12.330 ± 0.213           0.001 ± \<0.001
  Karavoate L                    −12.807 ± 0.200           0.0004 ± \<0.001
  Karavoate N                    −12.160 ± 0.560           0.002 ± 0.001
  Karavoate P                    −13.537 ± 0.605           0.0002 ± \<0.001
  Latilagascene I                −11.147 ± 0.561           0.009 ± 0.009
  Latilagascenes D               −12.220 ± 0.370           0.001 ± 0.001
  Lonafarnib                     −11.433 ± 0.087           0.004 ± 0.001
  Metergoline                    −9.737 ± 0.029            0.073 ± 0.004
  Pimozide                       −10.220 ± 0.324           0.031 ± 0.025
  Tariquidar                     −11.273 ± 0.274           0.006 ± 0.002
  Tribenzoylbalsaminol F         −12.403 ± 0.118           0.001 ± \<0.001
  Zosuquidar                     −11.257 ± 0.361           0.006 ± 0.004
  Elacridar (positive control)   −11.093 ± 0.361           0.008 ± 0.004
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###### 

Lowest binding energies (LBE) and predicted inhibition constants obtained by molecular docking of the top 20 P-gp substrates.

  P-gp substrate                   AutoDock LBE (kcal/mol)   Predicted Inhibition Constant (µM)
  -------------------------------- ------------------------- ------------------------------------
  Acetyldigoxin                    −11.767 ± 0.480           0.003 ± 0.002
  Bromocriptine                    −12.360 ± 1.02            0.002 ± 0.001
  Candesartan Cilexetil            −11.153 ± 0.370           0.007 ± 0.004
  Cepharanthin                     −10.753 ± 0.006           0.013 ± \<0.001
  Cytochalasin E                   −10.957 ± 0.006           0.093 ± 0.001
  Digitoxin                        −11.390 ± 0.517           0.006 ± 0.004
  Digoxin                          −11.500 ± 0.151           0.004 ± 0.001
  Dihydroergocristine              −11.670 ± 0.056           0.003 ± \<0.001
  Dofequidar                       −10.970 ± 0.351           0.010 ± 0.006
  Ergocristine                     −12.407 ± 0.012           0.001 ± \<0.001
  Ergotamine                       −11.227 ± 0.150           0.006 ± 0.001
  Irinotecan                       −11.380 ± 0.020           0.005 ± \<0.001
  Itrazole                         −10.843 ± 0.186           0.012 ± 0.003
  Jolkinoate L                     −10.643 ± 0.681           0.022 ± 0.016
  Latilagascenes E                 −11.770 ± 0.185           0.002 ± 0.001
  Latilagescene G                  −12.500 ± 0.316           0.001 ± \<0.001
  Mk-3207                          −11.650 ± 0.020           0.003 ± \<0.001
  Paclitaxel                       −9.607 ± 0.359            0.103 ± 0.065
  Telcagepant                      −9.333 ± 0.021            0.144 ± 0.005
  Vindoline                        −7.337 ± 0.211            4.363 ± 1.389
  Doxorubicin (positive control)   −11.070 ± 0.135           0.008 ± 0.002
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###### 

Lowest binding energies (LBE) and predicted inhibition constants obtained by molecular docking of the non-modulators.

  P-gp Inhibitor   AutoDock LBE (kcal/mol)   Predicted Inhibition Constant (µM)
  ---------------- ------------------------- ------------------------------------
  Oxprenolol       −5.743 ± 0.398            70.273 ± 40.057
  Promazine        −6.933 ± 0.021            8.273 ± 0.262
  Riluzole         −5.380 ± 0.010            114.080 ± 2.326
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###### 

Average values of descriptors for inhibitors and substrates.

  Descriptor              Inhibitor           Substrate
  ----------------------- ------------------- -------------------
  cLogP                   3.498 ± 2.464       3.134 ± 2.962
  Total surface area      311.199 ± 188.142   461.870 ± 286.187
  Shape index             0.529 ± 0.125       0.429 ± 0.081
  Molecular flexibility   0.395 ± 0.141       0.332 ± 0.114
  Rotatable bonds         6.799 ± 12.158      9.818 ± 11.778
  Aromatic rings          1.450 ± 1.168       1.918 ± 1.330
  Aromatic atoms          8.237 ± 6.470       10.759 ± 7.098
  Symmetric atoms         2.649 ± 3.637       3.582 ± 4.477
  Aromatic nitrogens      0.301 ± 0.772       0.559 ± 1.141
  Basic nitrogens         0.441 ± 0.625       0.659 ± 0.762
  Acidic oxygens          0.117 ± 0.361       0.171 ± 0.462
